Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?

Glioblastoma is the most common malignant brain tumor, representing 53.8% of all gliomas (1). Despite standard of care treatment with radiation and temozolomide chemotherapy, glioblastoma has a dismal prognosis with median survival of 14.6 months (2) and 20.9 months with addition of tumor-treating fields (Optune) (3). After tumor progression, treatment with re-irradiation and/or systemic therapy has yet to show improved overall survival leading to disagreement as to the best management of the patient who has progressed after standard of care treatment.

We read the article by Shi et al. (4) with great interest and would like to thank the authors for attempting to shed light on the optimal treatment for recurrent glioblastoma. The authors analyzed 637 patients from the RTOG 0525 study (5) with newly diagnosed glioblastoma treated with dose-dense temozolomide who had information regarding their management after tumor progression. The study divided patients in 4 groups according to their non-protocol management after progression, evaluating those that received radiation treatment alone, systemic therapy alone, radiation and systemic therapy, and patients who received neither radiation nor systemic treatment. Their analysis suggests that there was significant survival benefit among patients receiving any salvage therapy (radiation alone 8.2 months, systemic therapy 10.6 months, and both radiation and systemic therapy 12.2 months) compared to those who received no treatment (4.8 months) after progression.

There remains no consensus on the optimal treatment of glioblastoma after progression, with many prospective studies failing to show survival benefit at recurrence even with Food and Drug Administration approved therapies such as bevacizumab or tumor-treating fields (6-8). The phase II trial by Vredenburgh et al. with bevacizumab plus irinotecan in recurrent glioblastoma showed a 6-month overall survival of 77% (7). Likewise, Friedman et al. were able to demonstrate a median overall survival of 10.7 months for those receiving bevacizumab and irinotecan (8).

The BELOB trial was on open-label trial for second-line chemotherapy where patients were randomized to receive bevacizumab, lomustine, or combination bevacizumab and lomustine (9). The patients receiving combination bevacizumab and lomustine had an overall 9-month overall survival rate of 63%, which was superior to the bevacizumab alone group of 38%, or 43% in the lomustine alone group. Shi et al. provide support for continued therapy beyond standard of care chemoradiation. Information on the specific agent or regimen delivered was known for only 54% of patients who received non-protocol systemic therapy, and details on type of radiation therapy after recurrence were not provided in the study (4). Thus, particular chemotherapy agents of benefit are unable to be elucidated from the article. Only clear finding was that those with no salvage treatment had the poorest survival among the four arms in the study.

Similarly, various retrospective studies evaluating the therapeutic contribution to stereotactic radiosurgery and bevacizumab after progression have shown survival and progression free survival benefit (10,11). The article by Shi et al. provides a larger retrospective analysis of patients treated with radiation therapy after progression in prospective phase III randomized trial, however, it remains limited by its retrospective nature. Additionally, the study suffers from relatively small patient population in some treatment groups. The analysis of 637 patients from RTOG 0525 was robust, however, their sub-analysis revealed only 64 patients who received both radiation and systemic therapy, and 24 patients who received radiation alone. There is limited data to draw a conclusion about how these subjects compare to their counterparts who did not receive re-irradiation.

Moreover, the finding that salvage treatment was associated with longer survival, may merely reflect the poor performance status of those who were not treated with salvage therapy. Patients with favorable performance status (KPS >70) in those receiving radiation therapy only was less common than in patients receiving both radiation therapy and systemic therapy, 71% vs. 92%, respectively. The higher percentage of favorable Karnofsky performance status (KPS) in those receiving combined radiation and systemic therapy suggests an overall poorer performance status in radiation only group compared to the combined treatment group. Likewise, those with no neurologic symptoms at randomization was higher in the combined therapy group as compared with the radiation therapy only treatment group, 42% vs. 25%, respectively. The RT only group has no survivors at 24 months as compared with all other groups, which is unexpected, and may reflect the patient population having a poorer performance status and neurologic symptoms.

Secondly, the author’s analysis of the RTOG 0525 study also found that after progression there did not appear to be a significant difference among patients receiving systemic or combined therapy compared to radiation alone. Survival models controlling for potential confounders showed that radiation alone had only modestly better survival (HR 0.74) compared to those that underwent systemic therapy either with (HR 0.44) or without radiation therapy (HR 0.42). In the study, no survival difference was seen between radiation only and those receiving systemic therapy either with radiation or alone. The optimal treatment of recurrent glioblastoma is yet to be established, making this evaluation of re-irradiation notable.

The sub-analysis of the RTOG 0525 study by Shi et al. provides support to additional treatment beyond tumor progression in glioblastoma patients treated with standard chemoradiation. Notably in the study, it did not appear to matter if patients had re-irradiation, they could simply receive systemic therapy as adding radiation to systemic therapy or treating with radiation alone have no difference. Or as the author points out, the survival difference in those receiving treatment may merely reflect selection bias against those with poorer expected prognosis and functional status. Clearer longitudinal studies with multiple therapeutic comparison arms are needed to help delineate the optimal treatment patterns in recurrent glioblastoma.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Hongcheng Zhu (Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China).

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.10.22). SK serves as an unpaid editorial board member of Translational Cancer Research from Aug 2019 to Jul 2021. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 204-2006. 2010. Available online: http://www.cbtrus.org/reports/reports.html
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005;352:987-96. [Crossref] [PubMed]
3. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 2017;318:2306-16. [Crossref] [PubMed]
4. Shi W, Scannell Bryan M, Gilbert MR, et al. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys 2018;100:38-44. [Crossref] [PubMed]
5. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91. [Crossref] [PubMed]
6. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48:2192-202. [Crossref] [PubMed]
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9. [Crossref] [PubMed]
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40. [Crossref] [PubMed]
9. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53. [Crossref] [PubMed]
10. Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2012;82:2018-24. [Crossref] [PubMed]
11. Park KJ, Kano H, Iyer A, et al. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: A case-control study. J Neurooncol 2012;107:323-33. [Crossref] [PubMed]